Patients with hepatitis B may benefit from peginterferon if they need a limited duration of therapy, have genotype A HBV, or have hepatitis D coinfection.
Following recent updates to the AASLD HBV guidelines, what criteria determine optimal therapy for immune-active CHB?
Listen to downloadable audio from a live Webinar in which Stefan Zeuzem, MD, assessed the clinical impact of new data reported at the Paris meeting and answered case questions from participants.
Listen to downloadable audio from a series of live Webinars by Robert S. Brown, Jr., MD, MPH, and Norah Terrault, MD, MPH, in which the impact of 2018 updates to expert HBV guidance recommendations is discussed and audience questions are answered.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.